US Patent

US12502357 — Formulations of enzalutamide

Method of Use · Assigned to Astellas Pharma Inc · Expires 2033-09-11 · 7y remaining

Vulnerability score 75/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects formulations of enzalutamide, a drug used to treat hyperproliferative disorders.

USPTO Abstract

This disclosure provides formulations of enzalutamide and their use for treating hyperproliferative disorders.

Drugs covered by this patent

Xtandi (enzalutamide) · Astellas Pharma

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-4363`	—	Xtandi
`U-4363`	—	Xtandi

Patent Metadata

Patent number: US12502357
Jurisdiction: US
Classification: Method of Use
Expires: 2033-09-11
Drug substance claim: No
Drug product claim: No
Assignee: Astellas Pharma Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.